SS-31: The First Drug to Fix Mitochondria Just Got FDA Approved
Biohackers have been injecting it for years. In September 2025, the FDA made it official — and the implications go well beyond the rare disease it was approved for. “The powerhouse of the cell.” You’ve heard it a thousand times. It’s the one biology fact everyone remembers, usually as a meme. But buried under the […]
Adamax: The Semax Upgrade That Biohackers Built Themselves
No pharma company. No clinical trials. Just peptide chemists, Russian neuroscience, and one of the most talked-about cognitive compounds in the advanced nootropic space. Most compounds in the nootropic space have a straightforward lineage — a university lab, a pharma company, a patent filing. Adamax has a stranger origin story. It wasn’t developed by a […]
Flmodafinil: Modafinil’s More Potent Little Brother
Same wakefulness, sharper focus, lower dose — and still flying under the regulatory radar. For now. If you’ve spent any time in nootropic circles, you know modafinil’s reputation. The “limitless pill” that isn’t quite limitless but is genuinely useful — a prescription wakefulness agent used for narcolepsy and shift work disorder that became a quiet […]
Bromantane: The Soviet-Era Adaptogen That Biohackers Are Rediscovering
Developed behind the Iron Curtain, banned at the Olympics, and largely forgotten in the West — until now. Most performance compounds have a straightforward story: someone identifies a mechanism, runs trials, files for approval. Bromantane has a different kind of origin. It was developed in the USSR in the 1980s as a military and cosmonaut […]
Retatrutide (GLP-3): The Triple-Agonist That’s Turning Heads in Weight Loss Research
What happens when you hit three metabolic targets at once? Researchers are finding out — and the early numbers are hard to ignore. If you’ve been following the GLP-1 space, you already know the story arc: semaglutide (Ozempic/Wegovy) shocked the world with 15% average weight loss, then tirzepatide (Mounjaro/Zepbound) came along and pushed that to […]